普洛药业：公司CDMO项目数保持较快增长，且逐渐进入商业化生产阶段，有助于CDMO产能利用率的回升

Core Viewpoint - The company has reported a significant increase in CDMO orders for Q1 2026, with a year-on-year growth of 100%, indicating strong confidence in achieving record profits in 2026 [1] Group 1: CDMO Project Growth - The company has experienced rapid growth in its CDMO projects in recent years, which are gradually entering the commercial production phase [1] - Increased utilization of CDMO capacity is expected as a result of this growth [1] Group 2: Production Capacity and Business Outlook - The CDMO projects and production capacity involve multiple subsidiaries and numerous production lines, meaning that strong performance in some production lines does not fully represent the overall business situation [1] - The company advises investors to rely on disclosed announcements for accurate performance expectations and to exercise caution in their analyses [1]